Free tool
FAERS Monitor: Alhemo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761428 or its brand name (Alhemo, Concizumab). Reports on generic versions are filed under their own applications.
Reports
45
Serious
36
80% of reports
Hospitalization
17
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemarthrosis11
- fall4
- condition aggravated3
- haematoma muscle3
- injection site pain3
- muscle haemorrhage3
- anti factor ix antibody increased2
- contusion2
- death2
- haematoma2
- haematuria2
- haemorrhage2
- haemorrhage subcutaneous2
- off label use2
- scleritis2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 27 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anti factor ix antibody increased | 2 | 58483.7 | 13847.1 | 58,481 |
| haematoma muscleSignal | 3 | 1173.6 | 392.7 | 2,434 |
| scleritis | 2 | 584.5 | 150.7 | 654 |
| haemarthrosisSignal | 11 | 574.4 | 343.5 | 5,731 |
| muscle haemorrhageSignal | 3 | 349.7 | 117.1 | 723 |
| haemorrhage subcutaneous | 2 | 263.7 | 68.0 | 294 |
| haematoma | 2 | 36.1 | 9.3 | 38 |
| haematuria | 2 | 27.3 | 7.0 | 28 |
| contusion | 2 | 9.7 | 2.5 | 8 |
| haemorrhage | 2 | 8.9 | 2.3 | 7 |
| fallSignal | 4 | 5.6 | 2.2 | 11 |
| condition aggravatedSignal | 3 | 4.6 | 1.5 | 5 |
| injection site painSignal | 3 | 4.6 | 1.5 | 5 |
| death | 2 | 1.1 | 0.3 | 0 |
| off label use | 2 | 1.1 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.